NCT07657884 Assessment of the Usefulness of SMI (Superb Vascular Imaging) for the Characterisation of Pancreatic Cystic Tumours (IMAKYST)
| NCT ID | NCT07657884 |
| Status | Recruiting |
| Phase | — |
| Sponsor | GCS Ramsay Santé pour l'Enseignement et la Recherche |
| Condition | Serous Cystadenoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-05-15 |
| Primary Completion | 2027-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2026-05-15 with a primary completion date of 2027-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A cystic lesion is an abnormal cavity formed within tissue or an organ, which may contain a liquid, semi-solid or gaseous substance. There are different types of pancreatic cystic lesions: lesions that may become cancerous and completely benign lesions that do not require monitoring, such as serous cystadenomas (SCs) and pseudocysts. Diagnostic difficulties mean that one in three patients with a SC undergoes unnecessary surgery with significant morbidity and mortality (risk of death). Currently, needle-based confocal laser endomicroscopy (nCLE) is the gold standard technique for the diagnosis of SC. SC is a lesion characterised by an extensive network of small blood vessels present in all the cyst walls and throughout the cyst's peripheral capsule. SMI (Superb Vascular Imaging) is a new ultrasound mode that improves the visibility of blood flow in the vessels without the injection of contrast medium (a diagnostic agent used for certain medical imaging examinations, most often administered intravenously), unlike nCLE. The Mermoz Endoscopy Centre will be equipped with an ultrasound console enabling SMI to be performed during an echoendoscopy examination. This technology is now available on the new EUS Aplio i800 console (Canon-Olympus), which is CE marked. To date, no data has been published on the potential of SMI to characterise and diagnose CS. This is why this clinical investigation is being conducted.
Eligibility Criteria
Inclusion Criteria: * Patient referred for confocal microscopy (nCLE) assessment of a pancreatic cyst of unknown origin * Patient with a cyst measuring more than 15 mm in diameter and at least one cyst cavity measuring ≥ 5 mm (to allow nCLE to be performed) * Patient registered with or covered by the National Health Service * French-speaking patient who has signed an informed consent form Exclusion Criteria: * Patient with calcifying chronic pancreatitis * Presence of a communication with the main pancreatic duct on MRI or endoscopic ultrasound * Patient whose lesion meets criteria for malignancy (tissue mass, metastases, ascites, vascular infiltration) * Patient with a contraindication to endoscopic ultrasound-guided puncture (haemostatic disorder) * Patient with a known allergy to fluorescein (used in nCLE) * Pregnant woman * Patient under legal guardianship: adults under guardianship, curatorship or other legal protection, or deprived of their liberty by judicial or administrative order * Hospitalised patient without consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07657884 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Serous Cystadenoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07657884 currently recruiting?
Yes, NCT07657884 is actively recruiting participants. Contact the research team at dr.napoleon@wanadoo.fr for enrollment information.
Where is the NCT07657884 trial being conducted?
This trial is being conducted at Lyon, France.
Who is sponsoring the NCT07657884 clinical trial?
NCT07657884 is sponsored by GCS Ramsay Santé pour l'Enseignement et la Recherche. The trial plans to enroll 60 participants.